The Case for Using Albuminuria in Staging Chronic Kidney Disease

被引：92

作者：

Gansevoort, Ron T. ^{[1
]}

de Jong, Paul E. ^{[1
]}

机构：

[1] Univ Groningen, Univ Med Ctr Groningen, Div Nephrol, Dept Med, NL-9713 EZ Groningen, Netherlands

来源：

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2009年 / 20卷 / 03期

关键词：

GLOMERULAR-FILTRATION-RATE; CARDIOVASCULAR EVENTS; DIABETIC NEPHROPATHY; RISK; PROTEINURIA; PREVALENCE; IRBESARTAN; MORTALITY; PREDICTS; US;

D O I：

10.1681/ASN.2008111212

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：465 / 468

页数：4

共 31 条

[21] Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor intervention trial [J].

Ishani, Areef ;

Grandits, Greg A. ;

Grimm, Richard H. ;

Svendsen, Kenneth H. ;

Collins, Allan J. ;

Prineas, Ronald J. ;

Neaton, James D. .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 17 (05) :1444-1452

[22] Clinical utility of trace proteinuria for microalbuminuria screening in the general population [J].

Konta T. ;

Hao Z. ;

Takasaki S. ;

Abiko H. ;

Ishikawa M. ;

Takahashi T. ;

Ikeda A. ;

Ichikawa K. ;

Kato T. ;

Kawata S. ;

Kubota I. .

Clinical and Experimental Nephrology, 2007, 11 (1) :51-55

[23] Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes [J].

Lewis, EJ ;

Hunsicker, LG ;

Clarke, WR ;

Berl, T ;

Pohl, MA ;

Lewis, JB ;

Ritz, E ;

Atkins, RC ;

Rohde, R ;

Raz, I .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :851-860

[24] PREDICTING DIABETIC NEPHROPATHY IN INSULIN-DEPENDENT PATIENTS [J].

MOGENSEN, CE ;

CHRISTENSEN, CK .

NEW ENGLAND JOURNAL OF MEDICINE, 1984, 311 (02) :89-93

[25] THE INCREASED RISK OF CORONARY HEART-DISEASE ASSOCIATED WITH NEPHROTIC SYNDROME [J].

ORDONEZ, JD ;

HIATT, RA ;

KILLEBREW, EJ ;

FIREMAN, BH .

KIDNEY INTERNATIONAL, 1993, 44 (03) :638-642

[26] Cost-effectiveness of early irbesartan treatment versus control (standard antihypertension medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease [J].

Palmer, AJ ;

Annemans, L ;

Roze, S ;

Lamotte, M ;

Lapuerta, P ;

Chen, R ;

Gabriel, S ;

Carita, P ;

Rodby, RA ;

De Zeeuw, D ;

Parving, HH .

DIABETES CARE, 2004, 27 (08) :1897-1903

[27] EARLY DETECTION OF PATIENTS AT RISK OF DEVELOPING DIABETIC NEPHROPATHY - A LONGITUDINAL-STUDY OF URINARY ALBUMIN EXCRETION [J].

PARVING, HH ;

OXENBOLL, B ;

SVENDSEN, PA ;

CHRISTIANSEN, JS ;

ANDERSEN, AR .

ACTA ENDOCRINOLOGICA, 1982, 100 (04) :550-555

[28] The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes [J].

Parving, HH ;

Lehnert, H ;

Bröchner-Mortensen, J ;

Gomis, R ;

Andersen, S ;

Arner, P .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :870-878

[29] Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial [J].

Tonelli, Marcello ;

Jose, Powell ;

Curhan, Gary ;

Sacks, Frank ;

Braunwald, Eugene ;

Pfeffer, Marc .

BMJ-BRITISH MEDICAL JOURNAL, 2006, 332 (7555) :1426-1429

[30]

VANDERVELDE M, 2009, J AM SOC NE IN PRESS

← 1 2 3 4 →